0001493152-26-023344
SEC filingIndaptus Therapeutics reported Q1 2026 net loss of $2.5M, cash burn of $7.0M, and cash of $1.5M, highlighting urgent need for additional capital.
Indaptus Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $2.5 million, a significant improvement from the $4.5 million loss in the same period last year. The reduction was driven by a $2.3 million decrease in R&D expenses to $0.5 million, primarily due to lower clinical costs from the Phase 1 study and reduced headcount, and a $0.1 million decrease in G&A expenses to $1.7 million. However, the company's cash position deteriorated sharply, with cash and equivalents falling from $8.5 million at year-end 2025 to $1.5 million as of March 31, 2026, after using $7.0 million in operating activities. Management commentary in the press release indicates a strategic reassessment of development priorities and resource allocation following recent executive management changes. The company also completed the conversion of all outstanding Series AA and Series AAA preferred stock into common stock during the quarter. With limited cash runway, Indaptus explicitly states the need to raise additional capital, and there is no assurance of financing availability. The forward-looking statements caution about the company's ability to continue as a going concern. The analyst consensus context provided shows historical EPS beats but forward estimates remain negative, underscoring the financial challenges.